|
Jun 18
|
UroGen Pharma Announces Pricing of Public Offering of Ordinary Shares and Pre-Funded Warrants
|
|
Jun 17
|
UroGen Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants
|
|
Jun 17
|
Urogen Pharma (URGN) Surges 9.7%: Is This an Indication of Further Gains?
|
|
Jun 13
|
UroGen Catapults On 'Unprecedented' Results For Gel-Based Cancer Drug
|
|
Jun 13
|
UroGen Announces Unprecedented 82.3% Duration of Response at 12 Months in the ENVISION Trial Investigating UGN-102 as Potentially the First FDA-Approved Non-Surgical Treatment for LG-IR-NMIBC
|
|
May 14
|
UroGen Pharma First Quarter 2024 Earnings: Misses Expectations
|
|
May 13
|
UroGen Pharma Ltd (URGN) Q1 2024 Earnings: Misses EPS Estimates, Revenue Slightly Above Expectations
|
|
May 13
|
UroGen Pharma Announces Date for ENVISION Data, New Long-Term Jelmyto Durability Data, and Reports 2024 First Quarter Financial Results and Business Highlights
|
|
May 12
|
Shareholders in UroGen Pharma (NASDAQ:URGN) have lost 67%, as stock drops 11% this past week
|
|
May 7
|
UroGen Pharma to Participate at Upcoming Investor Conferences
|
|
May 5
|
New Real-World Retrospective Analysis Presented at AUA 2024 Reports 86% Recurrence-Free Survival (RFS) at 24 Months with JELMYTO® Across All Studied Patient and Disease Characteristics in Cohort of Responders to Induction Therapy
|
|
May 4
|
UroGen Announces Results from ATLAS Showing Robust UGN-102 Durability of Response in New and Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer at AUA 2024
|
|
May 4
|
New Real-World Study on Retrograde Instillation of JELMYTO® for Treatment of Low-Grade Upper Tract Urothelial Cancer Reports Similar Complete Response Rate and Lower Stricture Rate Compared to OLYMPUS Pivotal Trial
|
|
May 3
|
UroGen Pharma to Report 2024 First Quarter Financial Results on Monday, May 13, 2024
|
|
Apr 22
|
Pharming Group (PHAR) Surges 7.2%: Is This an Indication of Further Gains?
|
|
Apr 17
|
UroGen Announces New Data Presentations at the American Urological Association 2024 Annual Meeting Highlighting Clinical Benefits of Our Portfolio for Urothelial Cancers
|
|
Apr 15
|
UroGen Announces FDA Acceptance of Investigational New Drug Application for UGN-103, a Next Generation Mitomycin-Based Formulation for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
|
|
Apr 14
|
UroGen Pharma Ltd.'s (NASDAQ:URGN) high institutional ownership speaks for itself as stock continues to impress, up 11% over last week
|
|
Apr 3
|
UroGen Pharma Files Patent Infringement Action Against Teva Pharmaceuticals
|
|
Mar 17
|
UroGen Pharma Full Year 2023 Earnings: Revenues Beat Expectations, EPS In Line
|